$0.70−0.03 (−3.83%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Innovative Eyewear (LUCY) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~40.1%/yr (FY21→FY25), net margin −285.2%.
The four lines that matter · FY21–FY25
Revenue ($K)▲62.6%
2,661.7
FY21→FY25CAGR +40.1%/yr
Net income ($K)▲2.3%
−7,591.2
FY21→FY25CAGR —
Free cash flow ($K)▼8.0%
−7,347.8
FY21→FY25CAGR —
Diluted EPS▲63.4%
−1.90
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−23.9%
5.2mn → 4.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$72.5K
+16.6% YoY in FY25 · 2.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-285¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 21.5% → 21.3%. Net margin -285.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.4742, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 3,753.6 | 2,661.7 | 1,636.4 | 1,152.5 | 659.8 | 690.7 | ▲62.6% | +40.1% |
Cost of revenue | 2,900.0 | 2,094.2 | 1,421.3 | 1,271.8 | 716.1 | 542.4 | ▲47.4% | +40.2% |
Gross profit | 853.6 | 567.5 | 215.2 | −119.3 | −56.3 | 148.3 | ▲163.7% | +39.9% |
Research & development | 820.2 | 725.4 | 819.4 | 662.2 | 524.7 | 86.3 | ▼11.5% | +70.3% |
Selling, general & admin | 5,933.0 | 5,225.8 | 4,473.3 | 3,887.0 | 2,796.7 | 1,386.1 | ▲16.8% | +39.3% |
Total operating expenses | 9,768.0 | 9,062.4 | 8,138.9 | 6,736.2 | 5,520.4 | 3,353.3 | ▲11.3% | +28.2% |
Operating incomefeeds ROC rank | −8,914.4 | −8,495.0 | −7,923.7 | −6,855.5 | −5,576.7 | −3,205.1 | ▼7.2% | — |
Other income, net | 0.0 | 0.0 | 0.0 | 192.1 | −105.2 | −39.4 | — | — |
Pretax income | −8,914.4 | −8,495.0 | −7,923.7 | −6,663.4 | −5,681.8 | −3,244.5 | ▼7.2% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −8,137.5 | −7,591.2 | −7,766.5 | −6,663.4 | −5,681.8 | −3,244.5 | ▲2.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | −1.90 | −5.19 | −10.87 | −0.87 | −0.62 | ▲63.4% | — |
Diluted shares (mn) | — | 3.99 | 1.50 | 0.61 | 6.53 | 5.25 | ▲166.8% | −6.6% |
| Margins | ||||||||
Gross margin10th pct in Healthcare | 22.7% | 21.3% | 13.1% | −10.4% | −8.5% | 21.5% | ▲8.2pp | −0.1pp |
Operating margin | −237.5% | −319.2% | −484.2% | −594.9% | −845.2% | −464.1% | ▲165.0pp | +144.9pp |
Net margin17th pct in Healthcare | −216.8% | −285.2% | −474.6% | −578.2% | −861.2% | −469.8% | ▲189.4pp | +184.6pp |
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Innovative Eyewear's revenue last fiscal year?
Innovative Eyewear reported revenue of $2,661.7K in fiscal 2025, up 62.6% from fiscal 2024.
What was Innovative Eyewear's net income?
Innovative Eyewear reported net income of −$7,591.2K in fiscal 2025, a net margin of −285.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

